KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $2.8 billion.

  • Abbott Laboratories' Cash from Operations rose 303.14% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 billion, marking a year-over-year increase of 447.98%. This contributed to the annual value of $8.6 billion for FY2024, which is 1786.26% up from last year.
  • Per Abbott Laboratories' latest filing, its Cash from Operations stood at $2.8 billion for Q3 2025, which was up 303.14% from $2.0 billion recorded in Q2 2025.
  • In the past 5 years, Abbott Laboratories' Cash from Operations registered a high of $3.1 billion during Q4 2021, and its lowest value of $1.0 billion during Q1 2024.
  • Moreover, its 5-year median value for Cash from Operations was $2.3 billion (2022), whereas its average is $2.2 billion.
  • In the last 5 years, Abbott Laboratories' Cash from Operations surged by 26881.12% in 2021 and then plummeted by 5008.3% in 2023.
  • Quarter analysis of 5 years shows Abbott Laboratories' Cash from Operations stood at $3.1 billion in 2021, then dropped by 24.16% to $2.3 billion in 2022, then soared by 30.61% to $3.0 billion in 2023, then dropped by 5.6% to $2.9 billion in 2024, then decreased by 2.82% to $2.8 billion in 2025.
  • Its Cash from Operations was $2.8 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $1.4 billion in Q1 2025.